Life sciences industry outlook for 2022 and beyond

To help life sciences companies prepare and execute their strategic plans for 2022 and beyond, our team of Value Architects™ have put together a list of important developments that should be considered by industry leaders.

Our complimentary whitepaper discusses:

  • Trends with capital markets and corporate governance
  • Changes in commercialization strategies
  • Opportunities for real-world data (RWD) and health economics and outcomes research (HEOR)
  • Impacts of the evolving regulatory landscape
  • And more

This is an area for any disclaimers, form submission notes, etc

Baker Tilly US, LLP, trading as Baker Tilly, is a member of the global network of Baker Tilly International Ltd., the members of which are separate and independent legal entities. © Baker Tilly US, LLP